Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia

[1]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[2]  P. Parikh,et al.  Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide. , 1999, The Journal of the Association of Physicians of India.

[3]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[4]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[5]  B. Cheson.  Infectious and immunosuppressive complications of purine analog therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Armitage,et al.  Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. , 1995, Clinical transplants.

[7]  D. Speiser,et al.  THE FREQUENCY OF PRETRANSPLANT DONOR CYTOTOXIC T CELL PRECURSORS WITH ANTI‐HOST SPECIFICITY PREDICTS SURVIVAL OF PATIENTS TRANSPLANTED WITH BONE MARROW FROM DONORS OTHER THAN HLA‐IDENTICAL SIBLINGS , 1993, Transplantation.

[8]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[9]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.